A randomised, double-blind, parallel groups, dose-finding, placebo-controlled, multi-centre, proof of concept study assessing the effect of 3-week treatment with 1 of 3 oral doses of quinagolide and placebo in preventing ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation

Trial Profile

A randomised, double-blind, parallel groups, dose-finding, placebo-controlled, multi-centre, proof of concept study assessing the effect of 3-week treatment with 1 of 3 oral doses of quinagolide and placebo in preventing ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Quinagolide (Primary)
  • Indications Ovarian hyperstimulation syndrome
  • Focus Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 01 Apr 2010 Results reported in Human Reproduction.
    • 17 Feb 2009 Actual patient numbers (182) added as reported by ClinicalTrials.gov.
    • 17 Feb 2009 Actual initiation date changed from May 2006 to Jun 2006 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top